Literature DB >> 10816204

Modified ultrafiltration improves carbon dioxide removal after cardiopulmonary bypass in infants.

R Aeba1, T Katogi, T Omoto, I Kashima, S Kawada.   

Abstract

Little is known about the role of modified ultrafiltration in ameliorating the adverse effects of the cardiopulmonary bypass on pulmonary function in infants. Twenty-nine nonrandomized consecutive infants (<12 months of age) who underwent unrestrictive ventricular septal defect closure between 1995 and 1998 were included in this study. Down's syndrome was associated in 9 patients. The actual ventilator settings were highly homogeneous among all patients and each time point in the study. Fourteen infants received modified ultrafiltration after the discontinuation of cardiopulmonary bypass. Fifteen untreated patients served as the control group. Correlates of cardiac and pulmonary functions for both groups were compared. The arterial carbon dioxide tension in the experimental group was significantly lower than in the control group from 20 to 240 min after bypass. Arterial oxygenation and pulmonary arterial pressure were similar in the 2 groups. Modified ultrafiltration improves carbon dioxide removal after cardiopulmonary bypass in infants. This may potentially convey a beneficial impact on hemodynamics.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10816204     DOI: 10.1046/j.1525-1594.2000.06487.x

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  2 in total

1.  Venoarterial modified ultrafiltration versus conventional arteriovenous modified ultrafiltration during cardiopulmonary bypass surgery.

Authors:  Rakesh Mohanlall; Jamila Adam; Arto Nemlander
Journal:  Ann Saudi Med       Date:  2014 Jan-Feb       Impact factor: 1.526

2.  Reevaluating the Importance of Modified Ultrafiltration in Contemporary Pediatric Cardiac Surgery.

Authors:  Vladimir Milovanovic; Dejan Bisenic; Branko Mimic; Bilal Ali; Massimiliano Cantinotti; Ivan Soldatovic; Irena Vulicevic; Bruno Murzi; Slobodan Ilic
Journal:  J Clin Med       Date:  2018-12-01       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.